Compare Matson Inc (MATX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Matson Inc trades at $221.38 (market cap $6.61B), while State Street SPDR S&P Biotech ETF trades at $153.99. The key difference: Matson Inc pays a 0.7% dividend while State Street SPDR S&P Biotech ETF pays none, and Matson Inc is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| MATX | XBI | |
|---|---|---|
Market Cap | $6.61B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $223.55 | $164.28 |
52-Week Low | $88.05 | $85.16 |
Enterprise Value | $7.21B | — |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $218.41, down 1.7% today but maintains a bullish technical outlook with strong moving averages and key support at $214. The company demonstrates solid fundamentals with a P/E of 16.48, net income margin of 12.92%, and consistent earnings beats in recent quarters. Recent news highlights preliminary Q2 2026 results expecting EPS of $4.12-$4.30 and a dividend increase to $0.38 per share, reflecting management confidence.
The investment outlook remains positive given analyst consensus of 63.64% buy ratings, robust cash flow from operations, and strategic fleet modernization. Key risks include exposure to Pacific trade volatility and potential economic slowdowns impacting shipping demand. The stock's current valuation and growth trajectory present a compelling opportunity for investors seeking stable dividends and earnings growth in the shipping sector.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
